Core Viewpoint - The low-temperature storage industry is under pressure, with Haier Biomedical reporting a decline in revenue and net profit for the first half of 2025, but showing signs of recovery compared to the second half of the previous year [1][2]. Financial Performance - Haier Biomedical's revenue for the first half of 2025 was 1.196 billion yuan, a year-on-year decrease of 2.27%, while net profit attributable to shareholders was 143 million yuan, down 39.09% [1]. - Despite the decline, revenue from low-temperature storage increased by 16.73% compared to the second half of the previous year [1]. New Industry Development - The proportion of revenue from new industries rose from 38% in 2023 to 47% in the first half of 2025, an increase of 7.27 percentage points year-on-year [2]. - Haier Biomedical has been actively acquiring companies in various sectors, including blood collection, temperature control, and laboratory solutions, to expand its new industry segment [3]. Market Position and Share - Haier Biomedical holds over 50% market share in plasma collection solutions and ranks among the top three in the automated medication market [4]. - The company has seen significant growth in its laboratory solutions, with its total organic carbon analyzers and UV spectrophotometers leading the domestic market [4]. International Expansion - Haier Biomedical is pursuing international markets with a localized strategy, having established a presence in over 150 countries and regions [5]. - In the first half of 2025, overseas revenue reached 427 million yuan, a year-on-year increase of 30.17%, with the second quarter showing a remarkable growth of 56.67% [6]. Future Outlook - The company anticipates further growth in overseas markets, particularly in Southeast Asia and the Middle East, driven by the expansion of medical infrastructure and the promotion of new industry solutions [7].

海尔生物形成低温存储、实验室解决方案、智慧用药和血液技术四大产 业格局，旨在提升信息透明度并满足投资者对非存储业务的结构性需求。 2025 年上半年，公司总收入 11.96 亿元，同比下降 2.3%，但海外市 场表现强劲，增长 30%，尤其在亚洲和欧洲区域。 国内市场面临压力，收入下降 14%，但公司通过扩大用户覆盖、提高市 场份额和提升团队能力积极应对，预计三、四季度收入将回升。 公司净利润同比下降 38%至 1.47 亿元，受材料毛利率、制造费用率和 物流成本上涨影响，预计下半年毛利率和净利率将提升。 实验室解决方案产业明确了打造实验室整体解决方案第一品牌的目标， 通过自动化与 AI 技术，已开发 200 多款产品，部分产品市场份额国内 领先。 智慧用药产业重点布局门诊药房、静脉中心及住院药房，实现全链条闭 环管理，并积极拓展海外市场。 血液技术产业通过采浆设备和耗材升级，市场占有率提升至 50%，并积 极布局海外市场，同时拓展血站产品线和临床治疗领域。 Q&A 公司在 2025 年中报中提到的产业布局有何变化？ 在 2025 年中报中，公司对产业布局进行了进一步深化。此前公司业务按照存 储产业和非存储新 ...

Core Viewpoint - The article discusses the announcement of the second batch of selected units for the "Innovation Task of Biomedical Materials" by the Ministry of Industry and Information Technology, highlighting various innovative materials and their respective companies involved in their development [2][3]. Group 1: Polymer Materials - Key materials include Polyethylene Terephthalate, Phosphorylcholine-based Polymers, High Purity Acrylic Monomers, and High Oxygen Permeability Silicones [3][4]. - Companies involved in these materials include China Petrochemical Corporation, Weigao Group, and Jiangsu New Vision Advanced Functional Fiber Innovation Center [4][5]. - Other notable materials are Dendritic Light-sensitive Smart Materials and Anti-thrombus New Materials, with companies like Jiangsu Baisei Biotechnology and BoHui (Zhejiang) Biotechnology [3][6]. Group 2: Metal Materials - Key materials in this category include Ultra-fine Crystal Titanium Rod Wire, Porous Tantalum, Zirconium Niobium Alloys, and High-end Stainless Steel Wire [7][8]. - Companies such as Baoji Xinnuo Special Materials and Shenzhen Shigesaisi Medical Technology are involved in the production of these materials [9]. Group 3: Inorganic Non-metallic Materials - Important materials include Degradable Semi-hydrated Calcium Sulfate, Silicon Nitride Ceramics, and 3D Printing Zirconia Ceramic Inks [10][11]. - Companies like Zhongding Kairui Technology and Beijing Bansai Technology are engaged in the development of these materials [11].

Core Viewpoint - Haier Biomedical is experiencing significant growth and transformation, with a focus on digitalization in the life sciences and medical device industry, achieving a revenue of 1.196 billion yuan and a net profit of 143 million yuan in the first half of 2025 [1] Group 1: Business Performance - The company has evolved from a single low-temperature storage manufacturer to a comprehensive life sciences and medical innovation enterprise, with new industries accounting for 47% of revenue in the first half of 2025, up from 38% in 2023 [1] - The smart medication sector has entered the top three in market share, while the blood technology sector holds over 50% market share in plasma collection, maintaining its position as the leader in China [2][3] Group 2: Technological Advancements - Haier Biomedical has established a multi-layer AI foundation, integrating AI with various applications, enhancing operational efficiency in smart medication and other sectors [4] - The company has seen a 48% increase in invention patents and has launched 10 new product solutions, reinforcing its technological barriers [5] Group 3: Market Expansion - The company has expanded its products to over 150 countries, with a 30% year-on-year increase in overseas revenue, particularly benefiting from localized strategies in markets like Japan and Brazil [6][7] - Strategic partnerships, such as with RAM Medical Group in Thailand, mark the company's entry into the Southeast Asian market, which presents significant growth potential [2] Group 4: Future Growth Drivers - The dual approach of internal R&D and external acquisitions is driving the company's continuous expansion, with a focus on optimizing industry structure and enhancing technological capabilities [6][7] - The company aims to leverage emerging markets' healthcare infrastructure development to further accelerate growth in smart medication and laboratory solutions [6]

Core Viewpoint - Haier Biomedical has transformed from a single low-temperature storage manufacturer to a comprehensive life sciences and medical innovation enterprise, with significant growth in new industries contributing to revenue [1][2]. Group 1: Financial Performance - In the first half of 2025, Haier Biomedical achieved operating revenue of 1.196 billion yuan and a net profit attributable to shareholders of 143 million yuan [1]. - The revenue share from new industries (smart medication, blood technology, laboratory solutions) increased from 38% in 2023 to 47% in 2025, a year-on-year increase of 7.27 percentage points [1][2]. Group 2: Industry Position and Innovations - The company holds over 50% market share in plasma collection solutions, maintaining its position as the leader in China [2]. - Haier Biomedical has upgraded its business model from "single equipment sales" to a comprehensive approach that includes smart devices, basic consumables, software platforms, and value-added services, enhancing customer loyalty and profitability [2]. Group 3: Research and Development - The company’s R&D investment increased by 11.61% year-on-year, accounting for 13.39% of operating revenue, focusing on AI technology integration and new product development [2]. Group 4: Market Expansion - Haier Biomedical's products are now available in over 150 countries and regions, with a 30% year-on-year increase in overseas revenue during the reporting period [3]. - The company has established localized platforms in five new countries, including Japan and Brazil, and anticipates growth in overseas markets due to the acceleration of medical infrastructure development in emerging markets [3].

青岛海尔生物医疗股份有限公司 第三届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 证券代码：688139 证券简称：海尔生物 公告编号：2025-043 （一） 审议通过《关于审议公司 2025 年半年度报告及摘要的议案》 经审议，公司监事会认为：公司 2025 年半年度报告及摘要的编制和审议程 序符合法律法规、《青岛海尔生物医疗股份有限公司章程》和公司内部管理制度 的各项规定。公司 2025 年半年度报告及摘要能够客观、真实地反映公司 2025 年半年度的经营情况，公司 2025 年半年度报告及摘要所披露的信息真实、准确、 完整，不存在任何虚假记载、误导性陈述或重大遗漏。 公司 2025 年半年度报告及摘要的内容详见与本公告同日在上海证券交易所 网站（http://www.sse.com.cn）披露的《青岛海尔生物医疗股份有限公司 2025 年半年度报告》和《青岛海尔生物医疗股份有限公司 2025 年半年度报告摘要》。 表决结果：同意 3 票，反对 0 票，弃权 0 ...

Core Viewpoint - The report outlines the progress and achievements of Qingdao Haier Biomedical Co., Ltd. in its "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" initiative for the first half of 2025, emphasizing the company's focus on AI integration, innovation, and market expansion to enhance competitiveness and shareholder value [1]. Group 1: Development and Innovation - The company accelerated the development of new productive forces, focusing on four major industries and enhancing global market competitiveness through an upgraded "four horizontal and four vertical" open R&D innovation system [1][2]. - The AI foundation is being strengthened with a multi-layered architecture that integrates AI technology with life sciences and medical innovation, resulting in the creation of 17 specialized intelligent agents across various fields [2][3]. - R&D investment reached 160 million yuan, accounting for 13.39% of revenue, with a 6% reduction in new product development cycles and a 48% increase in the number of invention patents [3]. Group 2: Product Solutions and Market Performance - In the low-temperature storage industry, the company launched innovative solutions focusing on automation and intelligence, achieving recognition from users and implementing various automated sample storage solutions across multiple institutions [4]. - The laboratory solutions sector saw breakthroughs with AI-driven automation, significantly improving the efficiency of PBMC separation and cell culture processes [4]. - The smart medication sector introduced several automated solutions, expanding services to over 300 medical institutions and achieving breakthroughs in overseas markets [5]. - The blood technology sector developed a new disposable leukocyte-reducing blood bag and an automated blood component separation machine, enhancing operational efficiency and safety for healthcare professionals [6]. Group 3: Market Expansion - Despite a 14.64% decline in domestic revenue to 761 million yuan, the company improved its market share in low-temperature storage and established a leading position in several new product categories [6][7]. - The overseas market showed strong growth, with revenue reaching 427 million yuan, a 30.17% increase year-on-year, and a 56.67% increase in the second quarter [7][8]. - The company implemented localized strategies in overseas markets, achieving significant product certifications and establishing local operational platforms in multiple countries [8]. Group 4: Corporate Governance and Investor Relations - The company enhanced its governance structure and compliance with legal regulations, holding multiple board meetings to ensure operational transparency and fairness [9][10]. - Investor relations activities included over 60 interactions with institutional investors, enhancing communication and transparency regarding the company's long-term value [10][11]. - The company has maintained a consistent dividend policy, with a total dividend payout of 788 million yuan since its listing, and initiated a new share repurchase plan to boost investor confidence [11][12]. Group 5: Employee Engagement and Incentives - The company adopted a "user value creation" model to maximize employee value, linking core staff incentives to company performance through a stock incentive plan [14].

Fundraising Overview - The company raised a total of RMB 1,156,905,698.60 after deducting issuance costs of RMB 4,670,375.54, with the net amount available for use being RMB 1,156,905,698.60 [1][4] - As of June 30, 2025, the company had utilized RMB 1,029,056,832.19 for fundraising projects, with a remaining balance of RMB 52,258.70 [1][4] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure proper use and management of the funds [1][2] - A tripartite agreement for the special account storage of fundraising was signed with Guotai Junan Securities and Bank of China, ensuring dedicated management of the funds [2][3] Fund Usage - The company has not used any idle funds for working capital during the reporting period, and all funds have been allocated according to the approved projects [4][6] - The company approved the use of RMB 15,000,000 of temporarily idle funds for cash management, with a maximum of RMB 4,700,000 allocated for permanent working capital [5][8] Compliance and Reporting - The company has adhered to all legal and regulatory requirements regarding the use of fundraising, with no violations reported [6][7] - The board of directors and supervisory board confirmed that the information disclosed regarding the fundraising usage is timely, accurate, and complete [7][9]

Core Viewpoint - Haier Biomedical is experiencing significant growth driven by its diversified business model and technological advancements in the life sciences and medical device sectors, with a focus on low-temperature storage, smart medication, and laboratory solutions [2][8]. Group 1: Financial Performance - In the first half of 2025, Haier Biomedical reported a revenue of 1.196 billion yuan and a net profit attributable to shareholders of 143 million yuan [2]. - The revenue from new industries (smart medication, blood technology, laboratory solutions) increased from 38% in 2023 to 47% in the first half of 2025, marking a year-on-year increase of 7.27 percentage points [3]. Group 2: Industry Position and Innovations - Haier Biomedical holds a leading position in various segments, with its smart medication market share ranking among the top three in the industry, and over 50% market share in blood plasma collection solutions [4]. - The company has introduced innovative products such as a disposable leukocyte-reducing blood bag and an automated blood component separator, enhancing customer loyalty and profitability [4]. Group 3: Technological Advancements - The company has increased its R&D investment by 11.61%, accounting for 13.39% of its revenue, focusing on AI technology integration and new product development [6]. - Haier Biomedical has established a multi-layer AI infrastructure, enabling deep integration of AI with various applications, such as the IncGPT-Med model for smart medication [6][7]. Group 4: Growth Strategy - The growth strategy is based on optimizing industry structure, expanding overseas, and leveraging both internal development and external acquisitions [8][9]. - The company has expanded its presence to over 150 countries, with a notable 30% year-on-year increase in overseas revenue during the reporting period [8]. Group 5: Future Outlook - Haier Biomedical aims to enhance its global competitiveness by focusing on four major industries and accelerating the development of innovative products and solutions [9].

Core Viewpoint - Haier Biomedical is experiencing significant growth through its diversified industrial structure and digital transformation strategy, achieving a revenue of 1.196 billion yuan and a net profit of 143 million yuan in the first half of 2025, driven by the synergy of four major industries and AI technology [1] Group 1: Industrial Performance - The company has transformed from a single low-temperature storage manufacturer to a comprehensive life sciences and medical innovation enterprise, with new industries (smart medication, blood technology, laboratory solutions) accounting for 47% of revenue in the first half of 2025, up from 38% in 2023 [2] - Each industry has established a leading position in its respective segment, with the smart medication sector addressing hospital drug management inefficiencies and achieving a top-three market share in automated medication [3] - The blood technology sector holds over 50% market share in plasma collection, introducing new products that enhance customer loyalty and profitability [3][4] Group 2: Technological Advancements - The company is leveraging AI and digital technologies to create a competitive edge, with R&D investment increasing by 11.61% to 13.39% of revenue, focusing on AI integration and new product development [5] - A multi-layered AI architecture has been established, enabling deep integration of AI with various applications, such as the IncGPT-Med model that improves medication handling efficiency [5][6] - The company has seen a 48% increase in patent applications and has established two new R&D centers, reinforcing its technological barriers [6] Group 3: Growth Strategy - The growth potential of Haier Biomedical is driven by a combination of industrial structure optimization, overseas expansion, and internal and external growth strategies [7] - The company has expanded its presence to over 150 countries, with a 30% year-on-year increase in overseas revenue, particularly benefiting from localized strategies in emerging markets [7][8] - Continuous R&D investment and strategic acquisitions have strengthened the company's capabilities in low-temperature storage and laboratory solutions, while also rapidly building platforms in smart medication and blood technology [8]